Dr. Walter Kaye

Magic Mushrooms to Treat Anorexia? All About Compass' Novel Phase 2 Trial Of Psychedelic's Main Compound

Psychedelics mental healthcare company Compass Pathways PLC. (NASDAQ: CMPS) has launched a phase 2 clinical study testing the efficacy of psilocybin with psychological support in people with anorexia nervosa.

2 New Studies Look At Compass Pathways' Psilocybin Drug For Anorexia And Depression

Compass Pathways (Nasdaq: CMPS), a company developing psychedelic pharmaceutical drugs for the mental health space, announced the publication of two new investigator-initiated studies using its flagship compound, COMP360.